Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB03002 vs Daily GH in Children with GHD
NCT00271518Phase 3Unknown
- Sponsor
- LG Chem
- Start
- Sep 2005
- Primary completion
- Dec 2013
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Eutropin Plus in growth hormone deficiency (GHD) (2 arms), sponsored by LG Chem. Primary endpoint: Height Velocity at 12 months. Status: unknown.
02
Drugs
Eutropin Plus
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00271518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271518.